Drugs

, Volume 70, Issue 11, pp 1381–1394

Current and Future Management Options for Myelodysplastic Syndromes

  • Jeffrey Bryan
  • Elias Jabbour
  • Hillary Prescott
  • Guillermo Garcia-Manero
  • Jean-Pierre Issa
  • Hagop Kantarjian
Review Article

Abstract

The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease. Despite this challenge, two recent developments have contributed significantly to advancements in the treatment of MDS: (i) improvements in classification systems and prognostic models; and (ii) the emergence of US FDA-approved agents such as lenalidomide, azacitidine and decitabine. Prior to these developments, supportive care measures consisting of blood and platelet transfusions, haematopoietic growth factors and antimicrobials remained standard of care for the treatment of MDS. As a result of these developments, clinicians are able to provide patient-tailored therapy for specific MDS subgroups. Clinical trials addressing combination therapies with multiple investigational agents as well as novel combination regimens are ongoing. This review focuses on supportive care modalities, the approved agents indicated for the treatment of MDS and future directions for the treatment of MDS, including agents under clinical investigation.

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Jeffrey Bryan
    • 1
  • Elias Jabbour
    • 1
  • Hillary Prescott
    • 1
  • Guillermo Garcia-Manero
    • 1
  • Jean-Pierre Issa
    • 1
  • Hagop Kantarjian
    • 1
  1. 1.Department of LeukemiaThe University of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations